Clinical Overview: Preventative Tools for Respiratory Syncytial Virus
Pharmacy Times
OCTOBER 23, 2023
RSV can create a problematic infection among children 12 months of age or younger, older adults, and in patients with immunocompromised conditions.
clinical respiratory-syncytial-virus 
AstraZeneca to acquire Icosavax
World Pharma News
DECEMBER 12, 2023
NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc.
Vaccines 
93
93 Join 33,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more
STAT
APRIL 9, 2024
A Pfizer vaccine showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, CNBC tells us. Landlords in places like greater Boston suddenly found they had vacant labs for the first time in a decade.
Vaccines 207
207 Vaccines 207
207 
Clinical Overview: Arexvy for Respiratory Syncytial Virus
Pharmacy Times
SEPTEMBER 1, 2023
Pharmacists play a critical role in educating patients on RSV prevention, how to recognize early symptoms, and when to seek medical help.
26 
Moderna's Novel mRNA Vaccine Shows Significant Efficacy Against RSV
PharmExec
DECEMBER 19, 2023
Pivotal trial findings show favorable clinical safety and efficacy data for mRNA-1345 in lowering the incidence of respiratory syncytial virus-associated lower respiratory tract disease.
Vaccines 52
52 Vaccines 52
52 
Pfizer announces positive top-line data for full season two efficacy of ABRYSVO® for RSV in older adults
World Pharma News
FEBRUARY 29, 2024
Pfizer Inc.
Immunity 103
103 
Palivizumab biosimilar by Mabxience Holding for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
Pharmaceutical Technology
JANUARY 4, 2024
Palivizumab biosimilar is under clinical development by Mabxience Holding and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections.
Biosimilars 40
40 Biosimilars 40
40 
US FDA approves ABRYSVO, Pfizer’s maternal RSV vaccine for infants
Express Pharma
AUGUST 21, 2023
ABRYSVO is unadjuvanted and composed of two preF proteins selected to optimise protection against RSV A and B strains and was observed to be safe and effective.
Vaccines 97
97 
Moderna finalises plans for UK mRNA vaccine manufacturing centre
European Pharmaceutical Review
DECEMBER 22, 2022
It also has potential to develop vaccines for other respiratory diseases, such as flu and respiratory syncytial virus. This will include running a significant number of clinical trials in the UK. The Moderna Innovation and Technology Centre (MITC) is intended to provide access to a UK-made supply of COVID-19 jabs.
Vaccines 129
129 Vaccines 129
129 
InvisiShield and Gladstone partner to develop intranasal preventatives
Pharmaceutical Technology
MARCH 21, 2023
Pre-clinical-stage biotechnology firm InvisiShield Technologies has partnered with Gladstone Institutes to develop intranasal preventatives against airborne viral infections including influenza, respiratory syncytial virus (RSV) and SARS-CoV-2.
Immunity 115
115 
EC grants marketing authorisation for GSK’s RSV vaccine Arexvy
Pharmaceutical Technology
JUNE 8, 2023
The European Commission (EC) has granted marketing authorisation for GSK’s respiratory syncytial virus (RSV) vaccine, Arexvy, for adults aged 60 years and above. The vaccine is indicated for active immunisation to prevent RSV-related lower respiratory tract disease (LRTD) in older adults.
Vaccines 59
59 Vaccines 59
59 
US FDA approves GSK’s Arexvy, world’s first RSV vaccine for older adults
Express Pharma
MAY 3, 2023
GSK announced that the US Food and Drug Administration (FDA) has approved Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. per cent (96.95% CI, 57.9–94.1,
Vaccines 66
66 
The invisible burden of RSV on older adults
pharmaphorum
DECEMBER 15, 2022
However, this has led to increased transmission of other respiratory diseases and, as we’re already seeing, there are now some very real concerns about a lesser-known virus – respiratory syncytial virus, or RSV. RSV is one of the most common respiratory viruses, causing coughs and colds during the winter months.
Mayo Clinic 69
69 
Moderna announces mixed success clinical updates for mRNA pipeline
Pharmafile
APRIL 12, 2023
Biotechnology company Moderna has announced clinical updates detailing the expansion and advancement of its mRNA pipeline, which includes treatments for COVID-19, influenza and respiratory syncytial virus (RSV), amongst others.
Vaccines 52
52 Vaccines 52
52 
Enanta secures FDA fast track designation for EDP-323 to treat RSV
Pharmaceutical Technology
APRIL 7, 2023
Enanta Pharmaceuticals has secured the US Food and Drug Administration’s (FDA) fast track designation for EDP-323 to treat respiratory syncytial virus (RSV). Consistent potency was also observed across a range of RSV clinical isolates in several cell types.
Dosage 110
110 Dosage 110
110 
Moderna signs ten-year deal with UK Government for vaccine production
Pharmafile
DECEMBER 23, 2022
The aim of the partnership is to generate a ready supply of UK-produced mRNA vaccines for COVID-19 and other infectious diseases like flu and respiratory syncytial virus (RSV). read more.
Vaccines 64
64 Vaccines 64
64 
FDA accepts application for nirsevimab as first protective option for RSV in infants
Pharmafile
JANUARY 5, 2023
The FDA has accepted an application for nirsevimab as the first protective option to combat respiratory syncytial virus (RSV) disease for all infants. If approved, the drug would become the first broadly protection option for RSV.
Enanta Pharmaceuticals’ EDP-323 Receives the US FDA’s Fast Track Designation for the Treatment of Respiratory Syncytial Virus
PharmaShots
APRIL 10, 2023
Shots: The US FDA has granted FTD for Enanta’s EDP-323 (L-protein inhibitor) for the treatment of the respiratory syncytial virus. EDP-323 is being studied in a P-I study evaluating the safety, tolerability, and PK with expected results in Q2’23 The company plans to present new preclinical PK data at ECCMID 20323.
Vaccines 40
40 Vaccines 40
40 
Moderna leads development of mRNA vaccines in infectious diseases: GlobalData
Express Pharma
JANUARY 29, 2024
GlobalData’s latest report, “mRNA Vaccines in Infectious Diseases-Market Overview”, reveals that several late-stage pipeline products are in development for various infectious diseases, such as influenza, respiratory syncytial virus (RSV), and cytomegalovirus, as well as for COVID-19.
Vaccines 101
101 Vaccines 101
101 
Pfizer maternal RSV vaccine approved
European Pharmaceutical Review
AUGUST 22, 2023
Abrysvo is approved for pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants. The US Food and Drug Administration (FDA)-approved treatment, is the first RSV vaccine indicated for infants from birth to six months of age.
Vaccines 85
85 Vaccines 85
85 
AI continues to gain momentum in the biopharmaceutical industry in 2023
Pharmaceutical Technology
JANUARY 16, 2023
Recent cases in the pharmaceutical sector include Poolbeg Pharma finding more than one respiratory syncytial virus (RSV) vaccine candidate with AI by going through a vast amount of early stage clinical data to prioritise candidates and reposition them as novel treatments for RSV infection.
UK, Moderna formalise 10-year vaccines alliance
pharmaphorum
DECEMBER 22, 2022
It also said the alliance will see Moderna invest in R&D in the UK over the next 10 years, including running a number of clinical trials and providing grant funding to UK universities, while the manufacturing facility will create more than 150 highly skilled jobs. The first vaccines are due to be produced at the new facility in 2025.
Vaccines 122
122 Vaccines 122
122 
NIH starts trial of Moderna’s mRNA Nipah virus vaccine
pharmaphorum
JULY 12, 2022
Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection caught from animals that has a fatality rate of between 40% and 70%, developed by mRNA specialist Moderna. “The need for a preventive Nipah virus vaccine is significant,” he added.
Vaccines 52
52 
Sanofi snaps up acne vaccine developer Origimm Bio
pharmaphorum
DECEMBER 1, 2021
The vaccine has just started clinical testing, but is designed to control the growth of C acnes on the skin and prevent it from damaging the cellular lining of pores, which can lead to scarring in severe acne cases. It will highlight vaccines for pneumococcal disease, meningitis, respiratory syncytial virus (RSV), influenza, and chlamydia.
Vaccines 105
105 Vaccines 105
105 
GenScript ProBio and RVAC partner for Covid-19 vaccine pDNA
Pharmaceutical Technology
FEBRUARY 23, 2023
This collaboration is expected to help expedite the clinical manufacturing of RVM-V001 and future mRNA-based vaccines that target infectious diseases such as Clostriodioides difficile infection (CDI) and Respiratory syncytial virus (RSV).
Vaccines 115
115 
PharmaShots Weekly Snapshots (June 19 – 23, 2023)
PharmaShots
JUNE 23, 2023
Gilead Receives EMA’s CHMP Positive Opinion of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer Date: June 23, 2023 | Tags: Gilead, Trodelvy, sacituzumab govitecan, HR+/HER2- Metastatic Breast Cancer, Regulatory, EMA, CHMP, Positive Opinion Sarepta Therapeutics’ Elevidys Receives the US FDA’s Accelerated (..)
Diabetes 40
40 
Ex-GSK vaccine chief to lead new UK biotech Vicebio
pharmaphorum
JULY 21, 2022
GSK’s former head of vaccines R&D – Dr Emmanuel Hanon – is heading up a new biotech called Vicebio that will go up against his former employer with a vaccine against respiratory syncytial virus (RSV) infections. ” He said. ” The post Ex-GSK vaccine chief to lead new UK biotech Vicebio appeared first on.
Vaccines 105
105 
Pfizer seeks to overturn three RSV vaccine patents held by GSK
pharmaphorum
JUNE 29, 2022
Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. com website.
Vaccines 103
103 Vaccines 103
103 
RVAC Medicines, A*STAR partner for mRNA manufacturing expertise
Pharmaceutical Technology
NOVEMBER 21, 2022
This will aid in the production of new raw materials and possible clinical-grade assets to develop mRNA vaccines and therapies for infectious diseases, as well as other ailments with unmet needs. It commenced a first-in-human clinical trial of the vaccines in September this year. .
Vaccines 52
52 Vaccines 52
52 
Merck gets on board with Moderna cancer vaccine in $250m deal
pharmaphorum
OCTOBER 12, 2022
“Continuing our strategic alliance with Merck is an important milestone as we continue to grow our mRNA platform with promising clinical programmes in multiple therapeutic areas.” The post Merck gets on board with Moderna cancer vaccine in $250m deal appeared first on.
Vaccines 105
105 Vaccines 105
105 
Risk adjusted net present value: What is the current valuation of Pharma Mar’s Ecubectedin?
Pharmaceutical Technology
JUNE 6, 2023
According to Globaldata, it is involved in 5 clinical trials, which are ongoing. The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Pharma Mar also offers kits used for diagnosis of influenza A and B and respiratory syncytial virus.
Compounding 40
40 Compounding 40
40 
GSK says RSV vaccine shows 94% efficacy in severe disease
pharmaphorum
OCTOBER 13, 2022
GSK’s vaccine against respiratory syncytial virus (RSV) is one of the top prospects in its pipeline, but also one with considerable competition, so needs strong data to support the programme. Top of the list is an overall protective efficacy against RSV lower respiratory tract disease of 82.6%
Vaccines 104
104 Vaccines 104
104 
GSK poaches Pfizer exec Dormitzer as new vaccines R&D chief
pharmaphorum
NOVEMBER 30, 2021
Dormitzer also took the lead on Pfizer’s respiratory syncytial virus (RSV) vaccine candidates, which are in late-stage testing and a race to market with GSK own experimental shots, as well as a BioNTech-partnered influenza jab BNT161, which started clinical trials earlier this year.
Vaccines 98
98 Vaccines 98
98 
Enanta lawsuit claims Pfizer’s Paxlovid infringes its patent
pharmaphorum
JUNE 23, 2022
Enanta has a long heritage in the development of antiviral compounds, working with AbbVie on therapies for hepatitis C virus (HCV) infection including Viekira Pak (paritaprevir/ritonavir/ombitasvir/dasabuvir) and Mavyret/Maviret (glecaprevir/pibrentasvir).
Compounding 52
52 
J&J ducks out of Bavarian Nordic vaccine partnerships
pharmaphorum
MAY 9, 2022
Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) and hepatitis B virus (HBV). ” The partners’ HPV candidate had advanced into phase 1/2 clinical trials.
Vaccines 52
52 Vaccines 52
52 
With filing due soon, Moderna stakes a claim to the RSV vaccine market
pharmaphorum
JANUARY 18, 2023
Moderna is looking to make a swift dash to the finish line with its respiratory syncytial virus (RSV) vaccine candidate, based on the same mRNA technology as its COVID-19 shots, with a filing in with the FDA in the first half of this year. Look out, Pfizer and GSK. for placebo.
Vaccines 52
52 
Trailing its RSV vaccine rivals, Bavarian Nordic cuts China deal
pharmaphorum
MARCH 22, 2022
Bavarian Nordic has licensed rights to its respiratory syncytial virus (RSV) vaccine in China and certain other Asian markets to Shanghai’s Nuance Pharma in a $225 million deal. million tied to clinical, regulatory, and commercial milestones as well as royalties on sales if MVA-BN RSV is launched in those markets.
Vaccines 52
52 Vaccines 52
52 
PharmaShots Weekly Snapshots (April 10 - 14, 2023)
PharmaShots
APRIL 14, 2023
Ocugen Reports Preliminary Results from the P-I/II Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Date: Apr 14, 2023 | Tags: Ocugen, OCU400, Retinitis Pigmentosa, Leber Congenital Amaurosis, Clinical Trial, P-I/II Trial Candesant Biomedical Receives the US FDA Clearance of Brella SweatControl Patch for Primary (..)
Diabetes 40
40 
GSK sees £20bn peak sales potential in late-stage pipeline
pharmaphorum
JUNE 23, 2021
GlaxoSmithKline’s pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory syncytial virus (RSV) vaccine and new blood cancer drug Blenrep. billion takeover of Tesaro in 2019. £1
Vaccines 101
101 Vaccines 101
101 
EHA21: Sanofi builds case for rare disease drug sutimlimab after FDA rejection
pharmaphorum
JUNE 11, 2021
“Based on the robust clinical evidence we have to-date, sutimlimab significantly inhibits haemolysis and has the potential to be an important new treatment for CAD,” said Karin Knobe, head of development, rare, and rare blood disorders at Sanofi.
Immunity 97
97 
Advancing Healthcare Accessibility: Point-of-Care Testing in Independent Pharmacies
Digital Pharmacist
AUGUST 31, 2023
Whether addressing acute pharyngitis, influenza, COVID-19, or other respiratory infections, the ability to swiftly identify causative agents empowers healthcare providers to make informed decisions that significantly impact patient outcomes. Navigating State Regulations for POCT State regulations influence rapid diagnostic testing protocols.
Philips makes another digital buy, as Thermo adds COVID-19 test maker
pharmaphorum
JANUARY 21, 2021
Capsule’s software is already used by more than 2,800 healthcare organisations around the world for device integration, vital signs monitoring and clinical surveillance services, including in intensive care units. That agreement comes a few weeks after Philips signed a $2.8 to develop a digital approach to personalised fertility treatment.
Sanofi doubles down on mRNA jabs with €400m-a-year R&D drive
pharmaphorum
JUNE 29, 2021
Sanofi has just significantly increased its investment in mRNA vaccine development, earmarking €400 million ($475 million) a year in R&D funding to an effort that it hopes will deliver at least six clinical-stage candidates by 2025. .
Vaccines 52
52 Vaccines 52
52 
Moderna facility in UK confirmed, part of 10-year deal with gov’t
pharmaphorum
JUNE 22, 2022
It will also serve as the focal point of a clinical trials hub for Moderna, and a collaboration with the UK health services on R&D. Construction of the facility is expected to start later this year, said the government, with the first mRNA vaccines due to be produced there in 2025.
Vaccines 59
59 Vaccines 59
59 
Let's personalize your content